Impact BioMedical, Inc.
0.5698-0.01 (-1.13%)
Oct 29, 3:58:26 PM EDT · NYSE American · IBO · USD
Key Stats
Market Cap
6.94MP/E (TTM)
-Basic EPS (TTM)
-3.16Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
Impact BioMedical posted minimal revenue of $7,000 from biotech retail sales in Q2 FY2025 ended June 30, 2025, up from zero a year earlier, yet operating losses widened to $1.2M from $626K on higher professional fees and other expenses. The six-month net loss ballooned to $15.6M from $1.9M, driven by a $12.9M fair-value hit on related-party debt now at $22.4M after amendments allowing equity settlement. Cash dipped to $624K amid $1.4M operating burn, with no financing inflows. In February 2025, it snapped up DSS PureAir assets for 545K shares, adding $486K inventory and Celios IP amortized over 1-17 years. A pending merger with Dr. Ashleys eyes Q4 close. Controls remain weak.
8-K
Debt converted to equity
Impact BioMedical Inc. settled its $12 million revolving note with DSS, Inc. by issuing 31,939,778 shares of common stock on July 21, 2025, wiping out all outstanding debt and related support from June 21 onward. This conversion, stemming from the original March 2023 loan amended in January 2024, clears the balance sheet while diluting existing shareholders. Debt-free now. The move strengthens liquidity but introduces equity overhang.
8-K
Merger with Dr Ashleys announced
Impact BioMedical entered a merger agreement on June 21, 2025, with Dr Ashleys Limited, positioning Impact shareholders to hold 4.80% of the combined PubCo while Dr Ashleys secures 94.20%. The deal, backed by voting agreements from 86.81% of Impact's shares, hands control to Dr Ashleys' team, renaming Impact to Dr Ashleys USA Inc. post-merger. Yet closing hinges on approvals and zero net debt.
10-Q
Q1 FY2025 results
Impact BioMedical posted a Q1 operating loss of $1.0M, up 31% y/y from $0.8M, driven by higher sales, general and administrative compensation and professional fees amid post-IPO execution, while research and development costs fell 44% y/y to $0.1M. Net loss widened to $1.3M from $1.0M y/y, with the gap to operating loss mainly from $0.3M interest expense on related-party debt; diluted EPS held steady at $(0.11) on 12.1M shares. Cash dipped to $1.3M from $2.0M q/q after $0.7M operating burn, offset slightly by $0.001M from notes receivable, with no capex disclosed for FCF. In February 2025, it acquired DSS PureAir assets for $1.2M in stock, adding $0.5M inventory and $0.3M intangibles amortized over 1-17 years. Related-party debt stood at $9.1M, maturing 2030 at WSJ Prime +0.5%. Licensing delays pose a key risk.
IPO
Employees
Sector
Industry
CBIO
Crescent Biopharma, Inc.
12.50+0.00
CRVO
CervoMed Inc.
6.88+0.14
IBIO
iBio, Inc.
1.54+0.15
IMA
ImageneBio, Inc.
8.79+0.09
INBS
Intelligent Bio Solutions Inc.
0.95-0.06
INMB
INmune Bio Inc.
1.82+0.00
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
NRXS
Neuraxis, Inc.
3.02+0.00
TIL
Instil Bio, Inc.
17.71-1.02
ZIVO
Zivo Bioscience, Inc.
16.99-0.01